Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: A propensity analysis

Marzia Lazzari, Maria Teresa Greco, Claudio Marcassa, Simona Finocchi, Clarissa Caldarulo, Oscar Corli

Research output: Contribution to journalArticle

Abstract

Background: World Health Organization step III opioids are required to relieve moderate-to-severe cancer pain; constipation is one of the most frequent opioid-induced side effects. A fixed combination, prolonged-release oxycodone/naloxone (OXN), was developed with the aim of reducing opioid-related gastrointestinal side effects. The objective of this study was to compare the efficacy and safety of prolonged-release oxycodone (OXY) alone to OXN in opioid-naïve cancer patients with moderate-to-severe pain. Methods: Propensity analysis was utilized in this observational study, which evaluated the efficacy, safety, and quality of life. Results: Out of the 210 patients recruited, 146 were matched using propensity scores and included in the comparative analysis. In both groups, pain intensity decreased by ≈3 points after 60days, indicating comparable analgesic efficacy. Responder rates were similar between groups. Analgesia was achieved and maintained with similarly low and stable dosages over time (12.0–20.4mg/d for OXY and 11.5–22.0mg/d for OXN). Bowel Function Index (BFI) and laxative use per week improved from baseline at 30days and 60days in OXN recipients (-16,P

Original languageEnglish
Pages (from-to)5863-5872
Number of pages10
JournalDrug Design, Development and Therapy
Volume9
DOIs
Publication statusPublished - Nov 2 2015

Fingerprint

Oxycodone
Opioid Analgesics
Naloxone
Neoplasms
Safety
Pain
Laxatives
Propensity Score
Constipation
Analgesia
Observational Studies
Analgesics
oxycodone naloxone combination
Quality of Life

Keywords

  • Analgesia
  • Cancer pain
  • Naloxone
  • Oxycodone
  • Propensity analysis

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients : A propensity analysis. / Lazzari, Marzia; Greco, Maria Teresa; Marcassa, Claudio; Finocchi, Simona; Caldarulo, Clarissa; Corli, Oscar.

In: Drug Design, Development and Therapy, Vol. 9, 02.11.2015, p. 5863-5872.

Research output: Contribution to journalArticle

Lazzari, Marzia ; Greco, Maria Teresa ; Marcassa, Claudio ; Finocchi, Simona ; Caldarulo, Clarissa ; Corli, Oscar. / Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients : A propensity analysis. In: Drug Design, Development and Therapy. 2015 ; Vol. 9. pp. 5863-5872.
@article{968da3e26d9c49e080edb557f0861d5e,
title = "Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-na{\"i}ve cancer patients: A propensity analysis",
abstract = "Background: World Health Organization step III opioids are required to relieve moderate-to-severe cancer pain; constipation is one of the most frequent opioid-induced side effects. A fixed combination, prolonged-release oxycodone/naloxone (OXN), was developed with the aim of reducing opioid-related gastrointestinal side effects. The objective of this study was to compare the efficacy and safety of prolonged-release oxycodone (OXY) alone to OXN in opioid-na{\"i}ve cancer patients with moderate-to-severe pain. Methods: Propensity analysis was utilized in this observational study, which evaluated the efficacy, safety, and quality of life. Results: Out of the 210 patients recruited, 146 were matched using propensity scores and included in the comparative analysis. In both groups, pain intensity decreased by ≈3 points after 60days, indicating comparable analgesic efficacy. Responder rates were similar between groups. Analgesia was achieved and maintained with similarly low and stable dosages over time (12.0–20.4mg/d for OXY and 11.5–22.0mg/d for OXN). Bowel Function Index (BFI) and laxative use per week improved from baseline at 30days and 60days in OXN recipients (-16,P",
keywords = "Analgesia, Cancer pain, Naloxone, Oxycodone, Propensity analysis",
author = "Marzia Lazzari and Greco, {Maria Teresa} and Claudio Marcassa and Simona Finocchi and Clarissa Caldarulo and Oscar Corli",
year = "2015",
month = "11",
day = "2",
doi = "10.2147/DDDT.S92998",
language = "English",
volume = "9",
pages = "5863--5872",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients

T2 - A propensity analysis

AU - Lazzari, Marzia

AU - Greco, Maria Teresa

AU - Marcassa, Claudio

AU - Finocchi, Simona

AU - Caldarulo, Clarissa

AU - Corli, Oscar

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Background: World Health Organization step III opioids are required to relieve moderate-to-severe cancer pain; constipation is one of the most frequent opioid-induced side effects. A fixed combination, prolonged-release oxycodone/naloxone (OXN), was developed with the aim of reducing opioid-related gastrointestinal side effects. The objective of this study was to compare the efficacy and safety of prolonged-release oxycodone (OXY) alone to OXN in opioid-naïve cancer patients with moderate-to-severe pain. Methods: Propensity analysis was utilized in this observational study, which evaluated the efficacy, safety, and quality of life. Results: Out of the 210 patients recruited, 146 were matched using propensity scores and included in the comparative analysis. In both groups, pain intensity decreased by ≈3 points after 60days, indicating comparable analgesic efficacy. Responder rates were similar between groups. Analgesia was achieved and maintained with similarly low and stable dosages over time (12.0–20.4mg/d for OXY and 11.5–22.0mg/d for OXN). Bowel Function Index (BFI) and laxative use per week improved from baseline at 30days and 60days in OXN recipients (-16,P

AB - Background: World Health Organization step III opioids are required to relieve moderate-to-severe cancer pain; constipation is one of the most frequent opioid-induced side effects. A fixed combination, prolonged-release oxycodone/naloxone (OXN), was developed with the aim of reducing opioid-related gastrointestinal side effects. The objective of this study was to compare the efficacy and safety of prolonged-release oxycodone (OXY) alone to OXN in opioid-naïve cancer patients with moderate-to-severe pain. Methods: Propensity analysis was utilized in this observational study, which evaluated the efficacy, safety, and quality of life. Results: Out of the 210 patients recruited, 146 were matched using propensity scores and included in the comparative analysis. In both groups, pain intensity decreased by ≈3 points after 60days, indicating comparable analgesic efficacy. Responder rates were similar between groups. Analgesia was achieved and maintained with similarly low and stable dosages over time (12.0–20.4mg/d for OXY and 11.5–22.0mg/d for OXN). Bowel Function Index (BFI) and laxative use per week improved from baseline at 30days and 60days in OXN recipients (-16,P

KW - Analgesia

KW - Cancer pain

KW - Naloxone

KW - Oxycodone

KW - Propensity analysis

UR - http://www.scopus.com/inward/record.url?scp=84946595529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946595529&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S92998

DO - 10.2147/DDDT.S92998

M3 - Article

AN - SCOPUS:84946595529

VL - 9

SP - 5863

EP - 5872

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -